P38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer.

ABSTRACT: FGFR signalling is one of the most prominent pathways involved in cell growth and development as well as cancer progression. FGFR1 amplification occurs in approximately 20% of all squamous cell lung carcinomas (SCC), a predominant subtype of non-small cell lung carcinoma (NSCLC), indicating FGFR as a potential target for the new anti-cancer treatment. However, acquired resistance to this type of therapies remains a serious clinical challenge. Here, we investigated the NSCLC cell lines response and potential mechanism of acquired resistance to novel selective FGFR inhibitor CPL304110. We found that despite significant genomic differences between CPL304110-sensitive cell lines, their resistant variants were characterised by upregulated p38 expression/phosphorylation, as well as enhanced expr

SUBMITTER: Zarczynska I 

PROVIDER: S-EPMC8699485 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature